Evaluating NouvSoma001 for treating Neuromyelitis Optica Spectrum Disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is a single-center, randomized, open-label, placebo-controlled, dose-escalation study aimed at assessing the safety, tolerability, and efficacy of NouvSoma001, which consists of extracellular vesicles derived from human-induced neural stem cells. The trial is divided into two parts: the first part involves a dose-escalation design with three cohorts receiving increasing doses of the treatment, while the second part will randomize participants to either the treatment or placebo group based on the findings from the first part. The study will enroll a total of 69 participants, with careful monitoring for dose-limiting toxicities during the initial phase.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients must meet the 2015 International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorder (NMOSD) and test positive for AQP4 antibodies.
2. Symptom onset occurred within 7 days prior to enrollment, with associated severe pain, lower limb motor dysfunction, or urinary/bowel impairment.
3. Males or Females aged between 18 and 65 years.
4. The Expanded Disability Status Scale (EDSS) score prior to the current disease episode is ≤ 4.
5. Female participants of childbearing potential must present a negative pregnancy test at screening and agree to use effective contraception throughout the study period.
6. Informed consent must be obtained from the patient or their legal representative, with a signed consent form must be provided.

Exclusion Criteria:

1. Abnormal laboratory indicators of the subjects need to be excluded, including, but not limited to, the following indicators:

   White blood cell count \< 3 × 10⁹/L Neutrophil count \< 1.5 × 10⁹/L Hemoglobin \< 85 g/L Platelet count \< 80 × 10⁹/L Serum creatinine \> 1.5 × ULN Total bilirubin \> 1.5 × ULN Aspartate aminotransferase (AST) \> 3 × ULN Alanine aminotransferase (ALT) \> 3 × ULN Alkaline phosphatase \> 2 × ULN (AST = Aspartate Aminotransferase; GOT = Glutamic-Oxaloacetic Transaminase; ALT = Alanine Aminotransferase; GPT = Glutamic-Pyruvic Transaminase)
2. Any contraindications to lumbar puncture.
3. Pregnant or breastfeeding women, and patients with plans to conceive during the trial.
4. Patients with a known history of allergies to human-derived biological products or those with an allergic predisposition.
5. Patients who have undergone hematopoietic stem cell transplantation or lymphatic irradiation before enrollment.
6. Patients who have participated in any other clinical trial within the last 3 months.
7. Patients with severe comorbidities, including immunodeficiency or coagulation disorders.
8. Patients with active suicidal ideation within 6 months before screening or have a history of suicide attempts within 3 years before screening.
9. Patients with severe psychiatric symptoms that prevent clinical cooperation.
10. Patients with positive for alcohol addiction or drug abuse.
11. Patients with malignant tumors.
12. Patients who have experienced any of the following events within 12 weeks before enrollment: myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Class IV heart failure.
13. Patients with persistent systemic infections and severe local infections.
14. Patients unable to undergo magnetic resonance imaging during the trial.
15. Patients deemed unsuitable for participation by the investigator.

Where it's running

• Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Dai-shi Tian, MD — Tongji Hospoital
• Study coordinator: Chuan Qin, MD
• Email: qinchuan712@126.com
• Phone: 86-27-83663337

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using ultra-high field and metabolic MRI to understand resilience and degeneration in the aging and diseased brain

  This project will try advanced 3T and 7T MRI scans, including sodium and phosphorus imaging, to see if metabolic and connectivity changes explain resilience and degeneration in adults with MS, NMOSD, MOGAD, Alzheimer’s, Parkinson’s, or healthy aging.

  Recruiting Assistance Publique Hopitaux De Marseille · Marseille · NCT07202494

• Universal CD19/BCMA CAR T-cell therapy for relapsed or refractory neurological autoimmune diseases

  This will test whether a single infusion of universal CD19/BCMA CAR T-cells given after chemotherapy helps adults with relapsed or refractory neurological autoimmune diseases who have CD19- or BCMA-positive B cells.

  Recruiting Early Phase 1 Tianjin Huanhu Hospital · Tianjin · NCT06939166

• Assessing genetic variations in patients with neuromyelitis optica and multiple sclerosis

  This study is trying to see if certain genetic differences in the FCGR3A gene are more common in Italian adults with neuromyelitis optica, MOGAD, or multiple sclerosis.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Roma · NCT06865274

• Treatment for acute episodes of neuromyelitis optica spectrum disorder using protein A immunoadsorption

  This study is testing whether a new treatment using protein A immunoadsorption can help people with neuromyelitis optica spectrum disorder feel better during acute flare-ups compared to just using high-dose steroids.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT06763848

• Evaluating JYP0061 for treating acute Neuromyelitis Optica Spectrum Disorders

  This study is testing a new treatment called JYP0061 to see if it can help people with acute Neuromyelitis Optica Spectrum Disorders feel better and stay safe while using it.

  Recruiting Phase 2 Guangzhou JOYO Pharma Co., Ltd · Changsha, Hunan · NCT06697535

• Observational study on CNS inflammatory demyelinating diseases in the Chinese population

  This study is looking to understand how certain brain diseases, like Multiple Sclerosis, affect people in China and what factors might influence their progression and treatment.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06541626

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.